Drug Profile
Research programme: Alzheimer's disease therapeutics - Alzinova
Alternative Names: ALZ-103; ALZ-301Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Alzinova
- Class Alzheimer vaccines; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Sweden (Parenteral)
- 19 Dec 2011 Preclinical trials in Alzheimer's disease in Sweden (Parenteral)